Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL (2014) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 145:491–501

Article  CAS  PubMed  Google Scholar 

Griggs et al (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol. https://doi.org/10.1200/JCO.2012.41.9564

Article  PubMed  PubMed Central  Google Scholar 

Kurian AW, Lichtensztajn DY, Keegan TH, Leung RW, Shema SJ, Hershman DL, Kushi LH, Habel LA, Kolevska T, Caan BJ, Gomez SL (2013) Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004–2007. Breast Cancer Res Treat 137:247–260

Article  CAS  PubMed  Google Scholar 

Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB, Ward KC (2012) Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 133:285–296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enewold L, Penn DC, Stevens JL, Harlan LC (2018) Black/white differences in treatment and survival among women with stage IIIB-IV breast cancer at diagnosis: a US population-based study. Cancer causes & control : CCC 29(7):657–665. https://doi.org/10.1007/s10552-018-1045-9

Article  PubMed  Google Scholar 

Zhang L, King J, Wu XC, Hsieh MC, Chen VW, Yu Q, Fontham E, Loch M, Pollack LA, Ferguson T (2019) Racial/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: findings from ten national program of cancer registries states. Cancer Epidemiol 58:1–7

Article  PubMed  Google Scholar 

Griggs et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. https://doi.org/10.1200/JCO.2006.10.2749

Article  PubMed  Google Scholar 

Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS (2008) Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. The Breast 17(6):646–653

Article  PubMed  Google Scholar 

Warnecke RB, Oh A, Breen N et al (2008) Approaching health disparities from a population perspective: the national institutes of health centers for population health and health disparities. Am J Public Health 98(9):1608–1615. https://doi.org/10.2105/AJPH.2006.102525

Article  PubMed  PubMed Central  Google Scholar 

Emerson MA, Reeder-Hayes KE, Tipaldos HJ, Bell ME, Sweeney MR, Carey LA, Earp HS, Olshan AF, Troester MA (2020) Integrating biology and access to care in addressing breast cancer disparities: 25 years’ research experience in the Carolina breast cancer study. Current Breast Cancer Rep 12:149–160

Article  Google Scholar 

Sparano JA, Gray RJ, Ravdin PM et al (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380(25):2395–2405. https://doi.org/10.1056/NEJMoa1904819

Article  CAS  PubMed  PubMed Central  Google Scholar 

USDA ERS - Rural-Urban Continuum Codes Documentation [Internet]. Available from: https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation/

Morimoto L, Coalson J, Mowat F, O’Malley C (2010) Factors affecting receipt of chemotherapy in women with breast cancer. Int J Women’s Health 9:107–122

Article  Google Scholar 

Neuner JM, Kong A, Blaes A, Riley D, Chrischilles E, Smallwood A, Lizarraga I, Schroeder M (2019) The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Res Treat 173:179–188

Article  PubMed  Google Scholar 

Spronk PE, van Bommel AC, Siesling S, Wouters MW, Peeters MV, Smorenburg CH (2017) Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: results of the Dutch national breast cancer audit. The Breast 36:34–38

Article  CAS  PubMed  Google Scholar 

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of clinical oncology update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–312. https://doi.org/10.1200/JCO.2007.14.2364. (Epub 2007 Oct 22 PMID: 17954709)

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version 4.2023 [registration required]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419

Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK (2012) Predictors of timing of adjuvant chemotherapy in older women with hormone receptor–negative, stages II–III breast cancer. Breast Cancer Res Treat 131:207–216

Article  CAS  PubMed  Google Scholar 

Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29(1):e18

Article  PubMed  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121

Article  CAS  PubMed  PubMed Central  Google Scholar